[go: up one dir, main page]

PE20061366A1 - Compuestos y composiciones como inhibidores de quinasa de proteina - Google Patents

Compuestos y composiciones como inhibidores de quinasa de proteina

Info

Publication number
PE20061366A1
PE20061366A1 PE2006000501A PE2006000501A PE20061366A1 PE 20061366 A1 PE20061366 A1 PE 20061366A1 PE 2006000501 A PE2006000501 A PE 2006000501A PE 2006000501 A PE2006000501 A PE 2006000501A PE 20061366 A1 PE20061366 A1 PE 20061366A1
Authority
PE
Peru
Prior art keywords
methyl
alkyl
compounds
benzamide
pyrimidin
Prior art date
Application number
PE2006000501A
Other languages
English (en)
Inventor
Advait Nagle
Nathanael Gray
Pingda Ren
Shuli You
Taebo Sim
Yi Liu
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of PE20061366A1 publication Critical patent/PE20061366A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE n ES 0-2; m ES 0-2; Y1 ES N CR5; R5 ES H, ALQUILO C1-C6; Y2 ES O, S; R1 ES H, ALQUILO C1-C6; R2 ES H, ALQUILO C1-C6; R3 ES H, HALOGENO, HIDROXILO, ALQUILO C1-C6, ALCOXILO C1-C6, ENTRE OTROS; R4 ES -NR5C(O)R6, -C(O)NR5R6; R6 ES ARILO C6-C10, HETEROARILO C5-C10, CICLOALQUILO C3-C10, ENTRE OTROS; R7 ES H, HALOGENO, HIDROXILO, ALQUILO C1-C6, ALCOXILO C1-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-[4-(4-ETIL-PIPERAZIN-1-ILMETIL)-3-TRIFLUORO-METIL-FENIL]-4-METIL-3-[3-METIL-3-(7H-PIRROLO-[2,3-d]-PIRIMIDIN-4-IL)-UREIDO]-BENZAMIDA; 3-(4-METIL-IMIDAZOL-1-IL)-N-{4-METIL-3-[3-METIL-3-(7H-PIRROLO-[2,3-d]-PIRIMIDIN-4-IL)-UREIDO]-FENIL}-5-TRIFLUORO-METIL-BENZAMIDA; N-{3-3-METOXI-5-[3-METIL-3-(7H-PIRROLO-[2,3-d]-PIRIMIDIN-4-IL)-UREIDO]-FENIL}-3-MOROFOLIN-4-IL-5-TRIFLUORO-METIL-BENZAMIDA; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS MODULAN LA ACTIVIDAD DE QUINASAS UTILES EN EL TRATAMIENTO DE MELANOMA
PE2006000501A 2005-05-13 2006-05-11 Compuestos y composiciones como inhibidores de quinasa de proteina PE20061366A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68068405P 2005-05-13 2005-05-13

Publications (1)

Publication Number Publication Date
PE20061366A1 true PE20061366A1 (es) 2007-01-05

Family

ID=37074687

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000501A PE20061366A1 (es) 2005-05-13 2006-05-11 Compuestos y composiciones como inhibidores de quinasa de proteina

Country Status (19)

Country Link
US (1) US8183248B2 (es)
EP (1) EP1891066B1 (es)
JP (1) JP5016593B2 (es)
KR (1) KR20080025039A (es)
CN (1) CN101175753B (es)
AR (1) AR056346A1 (es)
AT (1) ATE492545T1 (es)
AU (1) AU2006247757B2 (es)
BR (1) BRPI0610278A2 (es)
CA (1) CA2607299C (es)
DE (1) DE602006019088D1 (es)
ES (1) ES2358344T3 (es)
GT (1) GT200600197A (es)
MX (1) MX2007014066A (es)
PE (1) PE20061366A1 (es)
PL (1) PL1891066T3 (es)
RU (1) RU2411242C2 (es)
TW (1) TW200726766A (es)
WO (1) WO2006124462A2 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101296928B (zh) * 2005-10-28 2011-01-19 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
PL2529622T3 (pl) 2006-09-22 2018-07-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej brutona
CA2681756C (en) * 2007-03-28 2015-02-24 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2070929A1 (en) 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP2265610B1 (en) * 2008-02-29 2012-12-12 Array Biopharma, Inc. Pyrazole [3, 4-b]pyridine raf inhibitors
CA2716947A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
EP2265574A1 (en) * 2008-02-29 2010-12-29 Array Biopharma, Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
TW200940540A (en) * 2008-02-29 2009-10-01 Array Biopharma Inc RAF inhibitor compounds and methods of use thereof
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
BRPI0908637B8 (pt) 2008-05-21 2021-05-25 Ariad Pharma Inc composto e composição farmacêutica do mesmo
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
CN102159214A (zh) 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
WO2011109593A1 (en) * 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Substituted-5-aminopyrrolo/pyrazolopyridines
MX387728B (es) 2010-06-03 2025-03-18 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
MX2014000338A (es) 2011-07-08 2014-05-01 Novartis Ag Derivados de pirrolo-pirimidina novedoso.
JP2014520863A (ja) 2011-07-13 2014-08-25 ファーマサイクリックス，インク． Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤
CN103073508B (zh) * 2011-10-25 2016-06-01 北京大学深圳研究生院 激酶抑制剂及治疗相关疾病的方法
US9782406B2 (en) 2011-10-25 2017-10-10 Peking University Shenzhen Graduate School Kinase inhibitor and method for treatment of related diseases
CA2854248A1 (en) * 2011-12-22 2013-06-27 F. Hoffmann-La Roche Ag 2,4-diamine-pyrimidine derivative as serine/threonine kinase inhibitors
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
KR20220093389A (ko) 2012-06-04 2022-07-05 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
UA125503C2 (uk) 2012-06-13 2022-04-13 Інсайт Холдинґс Корпорейшн Заміщені трициклічні сполуки як інгібітори fgfr
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
MA38183A1 (fr) 2012-11-15 2017-03-31 Pharmacyclics Inc Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
WO2014145576A2 (en) 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
WO2014172644A2 (en) 2013-04-19 2014-10-23 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP6800750B2 (ja) 2013-08-02 2020-12-16 ファーマサイクリックス エルエルシー 固形腫瘍の処置方法
WO2015023703A1 (en) 2013-08-12 2015-02-19 Pharmacyclics, Inc. Methods for the treatment of her2 amplified cancer
EA201690618A1 (ru) 2013-09-30 2016-09-30 Фармасайкликс Элэлси Ингибиторы тирозинкиназы брутона
JP2017509336A (ja) 2014-03-20 2017-04-06 ファーマサイクリックス エルエルシー ホスホリパーゼｃガンマ２及び耐性に関連した変異
CN106999494A (zh) 2014-08-01 2017-08-01 药品循环有限公司 布鲁顿酪氨酸激酶的抑制剂
MX2017001671A (es) 2014-08-07 2017-07-04 Pharmacyclics Llc Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
UA121669C2 (uk) 2015-02-20 2020-07-10 Інсайт Корпорейшн Біциклічні гетероцикли як інгібітори fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
CN105801584B (zh) * 2016-03-16 2019-03-05 中国药科大学 新型芳酰胺类Raf激酶抑制剂及其制备方法和用途
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN112566912A (zh) 2018-05-04 2021-03-26 因赛特公司 Fgfr抑制剂的盐
SI3788047T1 (sl) 2018-05-04 2024-11-29 Incyte Corporation Trdne oblike inhibitorja fgfr in postopki priprave le-teh
CN109374896A (zh) * 2018-11-22 2019-02-22 中山大学孙逸仙纪念医院 Plk3前列腺癌预后诊断检测试剂及其试剂盒
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4045151A1 (en) 2019-10-14 2022-08-24 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069695A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Derivatives of an fgfr inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE265458T1 (de) 1998-06-19 2004-05-15 Pfizer Prod Inc Pyrrolo(2,3-d)pyrimidin-verbindungen
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
HRP20020509B1 (en) 1999-12-10 2005-06-30 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
ATE423120T1 (de) 2000-06-26 2009-03-15 Pfizer Prod Inc Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe
SG145748A1 (en) * 2003-08-15 2008-09-29 Irm Llc 6-substituted anilino purines as rtk inhibitors
US7338957B2 (en) * 2003-08-28 2008-03-04 Irm Llc Compounds and compositions as protein kinase inhibitors
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP5016593B2 (ja) 2012-09-05
KR20080025039A (ko) 2008-03-19
CA2607299C (en) 2013-05-07
PL1891066T3 (pl) 2011-05-31
WO2006124462A2 (en) 2006-11-23
US20090118273A1 (en) 2009-05-07
GT200600197A (es) 2007-03-28
ATE492545T1 (de) 2011-01-15
CN101175753B (zh) 2011-03-23
DE602006019088D1 (de) 2011-02-03
BRPI0610278A2 (pt) 2010-06-08
CA2607299A1 (en) 2006-11-23
TW200726766A (en) 2007-07-16
JP2008540556A (ja) 2008-11-20
AR056346A1 (es) 2007-10-03
EP1891066B1 (en) 2010-12-22
AU2006247757A1 (en) 2006-11-23
AU2006247757B2 (en) 2009-08-27
US8183248B2 (en) 2012-05-22
ES2358344T3 (es) 2011-05-09
MX2007014066A (es) 2008-02-11
EP1891066A2 (en) 2008-02-27
RU2007145935A (ru) 2009-06-20
CN101175753A (zh) 2008-05-07
RU2411242C2 (ru) 2011-02-10
WO2006124462A3 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
PE20061366A1 (es) Compuestos y composiciones como inhibidores de quinasa de proteina
PE20061436A1 (es) Derivados de amida sustituida como inhibidores de proteina quinasa
PE20120370A1 (es) Derivados de 2,4-diaminopirimidinas como inhibidores de ptk2
HRP20050714B1 (hr) Aminoheteroarilni spojevi kao inhibitori proteinskih kinaza
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
DE602006007012D1 (de) Pyridinderivate als dipeptedyl-peptidase-hemmer
PE20051142A1 (es) Derivados de 4-benzimidazol-2-il-piridazin-3-ona, preparacion para los mismos
PE20120861A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20074634L (no) Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer
CY1111752T1 (el) Πυρρολοπυραζολες, δυναμικοι αναστολεις κινασης
PE20060438A1 (es) Compuestos de urea como moduladores del sarcomero
PE20110223A1 (es) DERIVADOS DE PIRROLO[2,3-e][1,2,4]TRIAZOLO[4,3-a]PIRAZIN, COMO INHIBIDORES DE QUINASA
UA87153C2 (ru) Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
PE20110063A1 (es) DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
NO20070489L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
PE20040647A1 (es) Inhibidores de cinasas de tirosina
HRP20050991A2 (en) Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors
EA200700185A1 (ru) Производные хиназолиндиона в качестве ингибиторов parp
ATE532781T1 (de) 5-(acylamino)indazol-derivate als kinase- inhibitoren
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
ATE475650T1 (de) Positive allosterische chinolon-m1- rezeptormodulatoren
EA200800240A1 (ru) Производные тиазола в качестве активатора амфк
UY29389A1 (es) Derivados sustituidos del ácido1-((4-((((3,3-dimetil-2-oxo-2,3-dihidro-1h-indol-1-il)carbonil)amino)metil)piperidin-1-il)metil)ciclobutanocarboxílico, sales farmaceuticamente aceptables, composiciones que los contienen y aplicaciones.

Legal Events

Date Code Title Description
FC Refusal